Fluorouracil (5-Fluorouracil, 5-FU)

For research use only. Not for use in humans.

製品コードS1209 別名:NSC 19893

Fluorouracil (5-Fluorouracil, 5-FU)化学構造

CAS No. 51-21-8

Fluorouracil (5-Fluorouracil, 5-FU, NSC 19893) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells. Fluorouracil induces apoptosis and can be used in the treatment of HIV.

サイズ 価格(税別) 在庫  
10mM (1mL in DMSO) JPY 24200 あり
JPY 26400 あり
JPY 38500 あり

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]




DNA/RNA Synthesis阻害剤の選択性比較


製品説明 Fluorouracil (5-Fluorouracil, 5-FU, NSC 19893) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells. Fluorouracil induces apoptosis and can be used in the treatment of HIV.
Thymidylate synthase [1]
(Tumor cells)

Adrucil is an analogue of uracil with a fluorine atom at the C-5 position in place of hydrogen. It rapidly enters the cell using the same facilitated transport mechanism as uracil. Adrucil is converted intracellularly to several active metabolites: fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine triphosphate (FUTP). The Adrucil metabolite FdUMP binds to the nucleotide-binding site of TS, forming a stable ternary complex with the enzyme and CH2THF, thereby blocking binding of the normal substrate dUMP and inhibiting dTMP synthesis. Metabolite of Adrucil also can be misincorporated into DNA, leading to DNA strand breaks and cell death. The pro-apoptosis effects of Adrucil may be related to its activation of tumor suppressor p53. Loss of p53 function reduces cellular sensitivity to Adrucil. [1] Adrucil is able to inhibit the survival and induce apoptosis of a board range of cancer cells. Adrucil suppresses viabilities of the nasopharyngeal carcinoma cell line CNE2 and HONE1 [2], pancreatic cancer cell lines Capan-1 [3], and human colon carcinoma cell line HT-29 [4] with IC50 of 9 μg/mL, 3 μg/mL, 0.22 μM, 2.5 μM, respectively.

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 NHHjZ5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mne3O|LDqGkEoB?= MYTJR|UxRTJyIN88[{9uVA>? NFT3[Y0zPDB7NUG3Oi=>
HT-29 NWPNWYJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TuTFczyqCqwrC= MY\JR|UxRiB{NTFOwIcwdUx? NHnHNnIzPDB7NUG3Oi=>
HL-60 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfGSFRFPzMEoHlCpC=> MYXJR|UxRThwNkCxJO69\y:vTB?= NEfHPWUzPDB7NUG3Oi=>
NCI-H292 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmW4O|LDqGkEoB?= NFn6V3lKSzVyPjCyOUDPxGdxbVy= NHrGVmYzPDB7NUG3Oi=>


Methods Test Index PMID
Western blot
p53 / PUMA / c-PARP; 

PubMed: 25965911     

(A) HCT-116 cells were treated with various doses of 5-FU for 24 hours (B) HCT-116 cells were treated with 200 uM 5-FU, then harvested at different time points after stimulation. The expression of p53, PUMA, cleaved PARP and P-Akt(S473) were detected by western blotting in different conditions.


PubMed: 23646193     

Cells were stained with an antibody against caveolin-3 (green) and with DAPI (blue). (A) control cells (top images), 10 mM 5-FU (middle images), 50 mM 5-FU (bottom images). Merged images are shown at the right of each panel.

phospho-histone H3 ; 

PubMed: 23646193     

Cells were grown for 24 h, treated with 5-FU and stained with an anti-phospho-histone H3 antibody (red) and with DAPI (blue). (A) control cells, (B) 0.1 mM 5-FU and (C) 1 mM 5-FU. 

p65 / p-p65(Ser536) / p53 / p-p53(Ser15); 

PubMed: 24587255     

E–H, Immunocytochemistry of p65 and p53 induction and localization by 5-FU treatment for the indicated cell lines. p65 (red), phosphor-p65 (Ser536; red), p53 (green), phospho-p53 (Ser15; red), and DAPI (blue) staining of the nucleus without (control) and with 5-FU treatment. 

Sox2 / Oct4 / Nanog / ABCG2; 

PubMed: 27009861     

(A) Immunofluorescence staining of Sox2, Oct4 and Nanog in HBE cells with or without 5-FU treatment. In untreated HBE cells, few Sox2, Oct4 or Nanog-positive cells were observed. After 5-FU treatment, the number of Sox2, Oct4 or Nanog-positive cells increased remarkably. Nuclei were counterstained with DAPI (blue). (B) Immunofluorescence staining of ABCG2 in HBE cells with or without 5-FU treatment. 


PubMed: 30111797     

Immunofluorescence detection of β-catenin in HCT-8 cells. Scale bar, 20 μm.

non-phospho β-catenin; 

PubMed: 28588704     

Effect of enhanced WNT signaling in Ell3 OE cells. Localization of non-phosphorylated β-catenin was analyzed by immunocytochemical staining in (A) control MCF-7 and (B) Ell3 OE treated with various 5-FU concentrations.

23646193 24587255 27009861 30111797 28588704
Growth inhibition assay
Cell viability; 

PubMed: 25965911     

Cells viability was analyzed using Cell Counting Kit-8 at 0, 3, 6, 12 and 24 hours after (A) 50, 100, 200, or 400 uM 5-FU treatment in HCT116 cells.

Cell proliferation; 

PubMed: 30250641     

(A) Cell proliferation assay with resveratrol in HCT116. Cells were treated with resveratrol at 0 ~ 200 μM for 72 hours and applied to MTS assay. (B) HCT116 cells were treated with 5-FU at 0~200 μM for 72 hours. (C)HCT116 cells were treated with resveratrol at 0 ~ 200 μM combined with 5-FU at 10 μM for 72 hours and applied to MTS assay. (D) DLD1 cell proliferation assay with resveratrol at 0 ~ 200 μM for 72 hours. (E) DLD1 cells were treated with 5-FU at 0~ 200 μM for 72 hours. (F) DLD1 cells were treated with resveratrol combined with 5-FU at 10 μM for 72 hours. Error bars represent standard deviation.

25965911 30250641
体内試験 Adrucil is widely used in the treatment of a range of cancers, including colorectal and breast cancers. [1] 100mg/kg Adrucil significantly suppresses tumor growth of murine colon carcinomas Colon 38 with tumor-doubling time (TD), growth-delay factor (GDF), and T/C of 26.5 days, 4.4, and 14%. [5]


細胞試験: [4]
- 合併
  • 細胞株: Human colon carcinoma cell line HT-29
  • 濃度: ~25 μM
  • 反応時間: 7 days
  • 実験の流れ: Growth inhibition is measured after treatment of cells with Adrucil for 7 days in 96-well plates (4000 HT-29 cells/well in RPMI 1640 medium with 10% dialyzed fetal bovine serum); increasing concentrations of Adrucil are added after allowing for cell attachment overnight. At the end of incubation, cells are rinsed three times with phosphate-buffered saline (pH 7.4), fixed with 10% trichloroacetic acid for 60 min at 4 ℃, washed five times with deionized water, and stained with 0.4% sulforhoda-mine B solution for 15 min at room temperature. Unstained sulforhodamine B is removed by rinsing with 1% glacial acetic acid. Afterwards, stained cell proteins are dried and dissolved with 10 mM Tris-HCl. The optical density value is measured using a detector at 540 nm wavelength.
- 合併
  • 動物モデル: Murine colon carcinomas Colon 38
  • 投薬量: 100 mg/kg
  • 投与方法: i.p. weekly

溶解度 (25°C)

体外 DMSO 26 mg/mL (199.87 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
saline (warming)

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。


分子量 130.08


CAS No. 51-21-8
Storage powder
in solvent
別名 NSC 19893
Smiles C1=C(C(=O)NC(=O)N1)F


投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
% DMSO % % Tween 80 % ddH2O





質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)


  • 質量





開始濃度 x 開始体積 = 最終濃度 x 最終体積


この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1



  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):




チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2


質量 濃度 体積 分子量


NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04158349 Recruiting Drug: Oxaliplatin|Drug: mFOLFIRI Colorectal Cancer|Appendiceal Cancer|Peritoneal Carcinoma University of Utah June 11 2020 Phase 1
NCT04370418 Not yet recruiting Drug: short course chemo-radiation with 5-fluorouracil Neo-adjuvant Short Course Chemo-radiation in Locally Advanced Cancer Rectum Assiut University May 2020 --
NCT04274933 Recruiting Drug: Venetoclax|Drug: Capecitabine Breast Cancer|Cancer AbbVie May 21 2020 Phase 1
NCT04274790 Not yet recruiting Procedure: Scheduled and planned surgery Cancer of Colon|Metastasis to Liver Centre Leon Berard March 1 2020 --



Handling Instructions


  • * 必須


  • 質問1:

    I was wondering if the product #s1209 (5-fluorouracil) is suitable to inject into mice ?

  • 回答:

    S1209 is suitable to inject (I.P.) into mice as indicating in this paper: http://www.ncbi.nlm.nih.gov/pubmed/8995503.

DNA/RNA Synthesisシグナル伝達経路

相関DNA/RNA Synthesis製品

Tags: Fluorouracil (5-Fluorouracil, 5-FU)を買う | Fluorouracil (5-Fluorouracil, 5-FU) ic50 | Fluorouracil (5-Fluorouracil, 5-FU)供給者 | Fluorouracil (5-Fluorouracil, 5-FU)を購入する | Fluorouracil (5-Fluorouracil, 5-FU)費用 | Fluorouracil (5-Fluorouracil, 5-FU)生産者 | オーダーFluorouracil (5-Fluorouracil, 5-FU) | Fluorouracil (5-Fluorouracil, 5-FU)化学構造 | Fluorouracil (5-Fluorouracil, 5-FU)分子量 | Fluorouracil (5-Fluorouracil, 5-FU)代理店
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID